A recent systematic pan‐cancer analysis of IGSF10 based on multiple databases has concluded that IGSF10 can serve as a valuable prognostic biomarker for certain types of cancers albeit its aberrant expression across different tumours, and IGSF10 expression was closely correlated with the tumour‐infiltrating immune cells, immune checkpoints, and immune modulators, suggesting IGSF10 as a potential immunotherapy target for several malignancies [15]. This evidence concerns the gene IGSF10 and cancer.